drugset / Trial / NCT02283268

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

NCT02283268

Phase 3 Completed 24 enrolled Baxalta now part of Shire
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von Willebrand disease (VWD).

Timeline

Start
2015-04-01
Primary completion
2016-07-06
Completion
2016-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant von Willebrand Factor Protein / enzyme biologic Intravenous